Key Sessions
Andrew Bellinger, MD, PhD
In Vivo Gene Editing for Atherosclerotic Cardiovascular Disease
Verve Therapeutics
Brian Cafferty, PhD
From Circles to Conjugates: Rethinking the Architecture of guide RNA
Beam Therapeutics
keyboard_arrow_right
Search & Filter keyboard_arrow_right
keyboard_arrow_left Hide
Day 2
keyboard_arrow_leftSearch & Filter
search
Streams
Day 2
search
Streams
8:00am - 8:40am
Registration and Coffee
Plenary Session
Showing 1 of 1 Streams
Plenary Session
8:40am - 8:45am
Chairperson’s Remarks
8:45am - 9:15am
In Vivo Gene Editing for Atherosclerotic Cardiovascular Disease
- Andrew Bellinger, MD, PhD - Chief Scientific Officer, Verve Therapeutics
9:15am - 9:45am
From Circles to Conjugates: Rethinking the Architecture of guide RNA
- Brian Cafferty, PhD - Director, Beam Therapeutics
9:45am - 10:15am
Improving Oligonucleotide Pharmacology Across Tissues and Modalities through Base, Sugar, and Backbone Modifications
- Michael Byrne, Ph.D. - Vice President, In Vivo and CNS Biology, Wave Life Sciences
10:15am - 10:55am
Networking Refreshment Break with Poster and Exhibit Viewing
Concurrent Conference Tracks
Showing 2 of 2 Streams
Track 1
Track 2
10:55am - 11:00am
Chairperson’s Remarks
11:00am - 11:30am
Bivalent Nucleic Acid Recognition and Its Applications in Targeting RNA Triplet-Repeats
- Danith Ly, Ph.D. - Professor of Chemistry, Carnegie Mellon University
11:30am - 12:00pm
Amide-Modified Oligonucleotides for Chemical Control of Functional RNAs
- Eriks Rozners, Ph.D. - Professor and Chair of Chemistry Department, Binghamton University
12:00pm - 12:30pm
Chemical Approaches to Enhance siRNA Selectivity
- Mehran Nikan, Ph.D. - Research Fellow, Ionis Pharmaceuticals Inc
10:55am - 11:00am
Chairperson’s Remarks
11:00am - 11:30am
Synthesizing Long Guide RNAs for In Vivo Prime Editing
- Rowshon Alam, Ph.D. - Senior Director, Head of Process Chemistry, Prime Medicine
11:30am - 12:00pm
Addressing the Regulatory Expectations for Guide RNA Quality While Providing Manufacturing Capacity
- Blake Unterreiner - Associate Vice President, Business Development & Customer Relations, Agilent Technologies
12:00pm - 12:30pm
Delivery of Genetic Medicine with Hydrophilic Nanoparticles
- Kunwoo Lee, PhD - Chief Executive Officer, GenEdit
12:30pm - 1:30pm
Networking Luncheon with Poster and Exhibit Viewing
Showing 2 of 2 Streams
Track 1
Track 2
1:30pm - 1:35pm
Chairperson’s Remarks
1:35pm - 2:00pm
Synthetic Strategy for Ligand Conjugated Oligonucleotides via Diamine Modified Stable Phosphoroamidite
- Mitsuaki Sekiguchi, Ph.D. - Principal Scientist, Biopharmaceutical Research Di, Shionogi & Co., Ltd.
2:00pm - 2:25pm
Impurity Analysis of Phosphoramidites for Manufacturing Oligonucleotide Therapeutics
- Gary Held - Staff Scientist, Analytical Development, Thermo Fisher Scientific
2:25pm - 2:50pm
Overcoming Oligonucleotide Manufacturing Challenges
- Loic Cornelissen, PhD - Sales Manager, PolyPeptide Group
2:50pm - 3:15pm
Going Large-scale with Manufacturing of Oligonucleotides
- Daniel Samson, PhD - Vice President, Head Oligonucleotides, Bachem AG
1:40pm - 1:45pm
Chairperson’s Remarks
1:45pm - 2:15pm
De Novo Discovery of Natural Product-like Thiopeptides with Designed Biological Activities
- Alexander Vinogradov, Ph.D. - Project Assistant Professor, The University of Tokyo
2:15pm - 2:45pm
Discovery of Macrocycles for Delivery of RNA and Targeted Radiopharmaceuticals
- Ratmir Derda, PhD - Founder and CSO, 48Hour Discovery and Associate Professor, Department of Chemistry, University of Alberta
2:45pm - 3:15pm
Macrocyclic Peptide Drug Development by Combining the Strengths of all Small Fragments, mRNA Display and AI Technologies
- Hwanho Choi, M.D., Ph.D. - CEO and Founder, Quantum Intelligence Corporation
3:15pm - 3:45pm
Networking Refreshment Break with Poster and Exhibit Viewing
Showing 2 of 2 Streams
Track 1
Track 2
3:45pm - 4:15pm
Oligonucleotide CMC Topic TBA
- Spenser Pruett - Scientist II, Process Development, Nitto Avecia
4:15pm - 4:45pm
Addressing Complex Oligonucleotide Therapeutics and Approach Towards Endotoxin Removal
- Juergen Mueller, PhD - Vice President of Commercial Operations, LGC Axolabs
4:45pm - 5:15pm
New Ligation Approach: Technology for High Quality Manufacturing of Over 150 mer RNA
- Masato Sanosaka, PhD - Group Leader of Research & Process Development, Ajinomoto Biopharma Services
3:45pm - 4:15pm
From Discovery to the Clinic: Development of a Novel Bioactive Peptide that Improves Mood and Cognition by Engaging the Gut-Brain Axis
- Kousaku Ohinata, Ph.D. - Founder and Scientific Advisor, Viage Therapeutics
4:15pm - 4:45pm
A Purely Thermodynamic Anti-prionic Mode of Action for Protein-misfolding Diseases is Realized by All-D-peptides
- Dieter Willbold, Ph.D. - Director and Full Professor, Forschungszentrum Jülich
4:45pm - 5:15pm
In Cellulo Library-derived Peptide-based Inhibitors of Alpha-synuclein Aggregation and Toxicity
- Jody Mason, PhD - Professor of Biochemistry, University of Bath
5:15pm - 6:15pm
Networking Cocktail Reception with Poster and Exhibit Viewing
Please join your fellow attendees in the exhibit hall for an evening of networking while enjoying beverages and appetizers.
6:15pm - 6:20pm
Close of Day Two
Get the Latest Event Updates
Sign up to get the latest event updates and information.
Filter
Streams
Choose Day